Inappropriate Vancomycin Therapeutic Drug Monitoring in Hospitalized Pediatric Patients Increases Pediatric Trauma and Hospital Costs

Abstract

OBJECTIVES The objective of this study was to measure the appropriateness of vancomycin monitoring in a pediatric tertiary care center and to evaluate the effectiveness of two interventions, autonomous pharmacy therapeutic drug monitoring and health care provider education, in reducing avoidable pediatric patient trauma and hospital cost. METHODS A retrospective chart review evaluating vancomycin therapeutic drug monitoring (TDM) in pediatric inpatients was performed before and after the introduction of an autonomous pharmacy TDM program and health care provider (HCP) education. RESULTS Thirty-five patients were included in our study, prior to any intervention. Of these, 9% of patients had trough concentrations appropriately deferred. Of the total of 64 trough concentrations obtained, 94% were considered to be inappropriate. After the start of the autonomous pharmacy TDM program, of the 54 eligible patients (111 troughs), 9% had trough concentrations appropriately deferred, and 34% were inappropriate. In the 3-month period following the introduction of HCP education in combination with pharmacy TDM, we identified 27 eligible patients. Among those, 15% of the patients had trough concentrations appropriately deferred. Of the 43 trough concentrations obtained, only 9% were considered to be inappropriate. The combination of pharmacy TDM with HCP education decreased annualized hospital cost by 60%, from $13,080 to $5232. CONCLUSIONS Inappropriate vancomycin TDM occurs commonly in our institution, resulting in unnecessary hospital cost and patient trauma. The combination of pharmacy TDM and HCP education significantly improved clinical practice; however, results were short-lived. Further interventions, such as computer based order entry, will likely be needed to reinforce and improve long-term TDM practice in pediatric patients.INDEX TERMS antibiotic stewardship, therapeutic drug monitoring, vancomycin J Pediatr Pharmacol Ther 2012;17(2):159-165

Voriconazole Therapeutic Drug Monitoring Practices in Intensive Care

“…Our data showed that voriconazole therapeutic drug monitoring would benefit from a multidisciplinary approach, in which the measured trough concentration is viewed in relation to the clinical context. Education alone will likely not be sufficient, because the effect of education on health care professionals is limited 21 and wanes with time, 21,22 especially in teaching hospitals because of frequent changes in staff. A more active role of the pharmacist improved vancomycin therapeutic drug monitoring in hospitalized pediatric patients.…”

Clinical Feasibility of Monitoring Enoxaparin Anti-Xa Concentrations: Are We Getting it Right?

“…18,[24][25][26][27][28][29][30][31] Incorrectly drawn anti-Xa levels have several important clinical implications. First, clinicians may be unaware that these are drawn inappropriately and interpret these levels as is.…”

“…18,[24][25][26][27][28][29][30][31] To date, there are no studies that primarily identify and describe the practicability of enoxaparin TDM in the literature. Herein, we describe the effectiveness and accuracy of anti-Xa monitoring for patients receiving treatment doses of enoxaparin in the acute care, hospital setting.…”

Impact of Initial Vancomycin Trough Concentration on Clinical and Microbiological Outcomes of Methicillin-ResistantStaphylococcus aureusBacteremia in Children

“…Because of the significant burden of MRSA infection in hospitals and the community, it is important to use vancomycin appropriately to ensure optimal drug exposure. Though some authors question the usefulness of therapeutic drug monitoring (TDM) of vancomycin and warn of unnecessary hospital costs, appropriate TDM is acknowledged as the most powerful method of adjusting vancomycin use in MRSA bacteremia (2). Studies of the pharmacokinetics and pharmacodynamics (PK/PD) of vancomycin have advocated that a ratio of the area under the curve to the minimum inhibitory concentration (AUC/MIC) of ≥ 400 is optimal for achieving clinical effectiveness in adults (3).…”